No Data
Mabwell: HK Listing to Help Capital Needs of Business, Promote Sustainable Development
Mabwell: To Find Appropriate Timing for H-Share Issuance
Mabwell (Shanghai) Bioscience: Board Approved Proposal to List on Hong Kong Exchange
Maiwei Biotechnology (688062.SH) plans to jointly invest in a bone health Innovative Drugs project with the Chongqing High-tech Zone Management Committee and others.
Maiwei Biological (688062.SH) announced that the company intends to cooperate with the Chongqing High-tech Industrial Development Zone Management Committee (abbreviated as...
Express News | Mabwell Shanghai Bioscience Says Co Plans to Issue H Shares, Seeking Listing on Mainboard in Hong Kong
Maiwei Biotechnology (688062.SH): Maiwei Chongqing plans to bring in investors and Taikang Biotechnology will increase capital with intangible Assets.
On December 15, Gelonghui reported that Maiwei Bio (688062.SH) announced its initiative to seize the opportunities presented by the new era of the national Western Development Global Strategy, deepening cooperation in the transfer and transformation of Technology achievements between the east and west, and expanding both domestic and international markets at important strategic pivot points. The company plans to sign a project investment cooperation agreement with the Chongqing High-tech Zone Management Committee and the Health Fund to jointly invest in the Maiwei Bio Bone Health Innovative Drugs project within the jurisdiction of the Chongqing High-tech Industrial Development Zone (hereinafter referred to as "Chongqing High-tech Zone"). The project is based on the advanced manufacturing base of biopharmaceutical CDMO in the Western (Chongqing) Science City, utilizing approximately 350.
No Data
